Valbiotis is preparing its entry into the Chinese food supplement market

Valbiotis, the French laboratory specializing in cardiometabolic health, recently delivered a significant order to its Chinese joint venture, Hangzhou Valbiotis Life Health Technology. This shipment, consisting of 50,000 units of the ValbiotisPRO® range, marks a key milestone towards the planned commercial launch in China by the end of 2026. The first products have been registered for distribution in Hong Kong and Singapore, enabling both physical and online sales.

Sales in China will be conducted through cross-border e-commerce platforms such as Tmall Global and JD Worldwide. This channel is strategic for meeting the growing demand for high-quality nutritional supplements. ValbiotisPRO® products will be offered at a premium price, significantly higher than in France, taking advantage of simplified customs regulations.

The joint venture also plans to expand into other Asian markets, thereby strengthening its position in the natural health products sector.